Two-fraction HDR Monotherapy for Localized Prostate Cancer

Recruiting now · Not applicable

Conditions studied: Prostate Adenocarcinoma, Localized Prostate Carcinoma

In brief

This is a single center single arm prospective pilot study investigating the safety of high dose rate (HDR) brachytherapy as monotherapy delivered in 2 fractions 3 hours apart. HDR monotherapy has been established as safe and effective in this context, however previous studies have delivered 2 fractions on separate days, or at least 6 hours apart. Clinically, this regimen, if shown to be safe and effective in future studies, has the potential to reduce operative resources and logistical stresses on brachytherapy departments.

Key facts

Study ID

NCT05665738

Run by

University of California, San Francisco

People needed

17

Starts

2024-09-11

Expected to finish

2029-02-28

Last updated by the study team

2026-06-05

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Participants must have histologically or cytologically confirmed diagnosis of prostate adenocarcinoma.
• National Comprehensive Cancer Network low to intermediate risk stratification.
• No prior treatment for prostate cancer and no prior androgen deprivation therapy.
• Age >=18 years.
• Eastern Cooperative Oncology Group (ECOG) performance status <2 (Karnofsky >60%.
• Eligible to undergo High dose rate (HDR) brachytherapy as monotherapy as determined by the treating radiation oncologist.
• Ability to understand and the willingness to sign a written informed consent document.
• Human immunodeficiency virus (HIV)-infected individuals on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial.
• For participants with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.
• Individuals with a history of hepatitis C virus (HCV) infection must have been treated and cured. For individuals with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.
• Individuals with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.

You may not qualify if…

• Any prior treatment for prostate cancer.
• Any prior androgen deprivation therapy.
• Is currently receiving any other investigational agents.
• Abnormal pre-brachytherapy assessment raising concern for undergoing HDR brachytherapy procedure.
• Contraindications to general anesthesia.
• Contraindications to radiotherapy.
• Prior cryosurgery or cryotherapy to the prostate.
• Prior transurethral resection of the prostate within the previous 6 months.

Where it is running

• University of California, San Francisco — San Francisco, California, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.